- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.01. | Novartis gene therapy set to enhance SMA treatment | ||
| 07.01. | Merck unveils new cyber-physical trust platform at CES 2025 | ||
| 06.01. | New prostate cancer test cuts biopsies by 50% in US | ||
| 06.01. | Amgen's lung cancer treatment gets conditional approval | ||
| 03.01. | NHS Confederation welcomes social care commission announcement | ||
| 03.01. | FDA approves Sequana Medical's Alfapump for ascites treatment | ||
| 02.01. | EC approves Rybrevant with Lazcluze for advanced lung cancer | ||
| 02.01. | UK regulator warns against buying weight-loss medicines without prescription | ||
| 17.12.24 | MindMed begins phase 3 study of MM120 for anxiety disorder | ||
| 17.12.24 | German cancer centre treats first patient with Elekta Evo | ||
| 16.12.24 | CSL receives positive opinion for garadacimab in hereditary angioedema | ||
| 16.12.24 | Beckley Psytech announces positive results for ELE-101 in depression trial | ||
| 12.12.24 | Bayer begins SOS1 inhibitor study treating advanced KRAS-mutated tumours | ||
| 12.12.24 | Leriglitazone meets primary endpoint in pivotal cALD trial | ||
| 11.12.24 | iOnctura achieves new clinical milestones in uveal melanoma therapy | ||
| 11.12.24 | Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy | ||
| 10.12.24 | Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis | ||
| 10.12.24 | CatalYm shows potential of visugromab for treating cachexia | ||
| 09.12.24 | Imfinzi receives NICE recommendation for lung cancer treatment | ||
| 09.12.24 | Poolbeg Pharma presents positive results for POLB 001 | ||
| 05.12.24 | Teva's Ajovy shows positive results in preventing pediatric migraines | ||
| 05.12.24 | NICE endorses Neuraxpharm's ublituximab for treating MS | ||
| 04.12.24 | Antag Therapeutics secures €80 million in weight loss therapy financing | ||
| 04.12.24 | Everest therapy shows promise in nephropathy trial | ||
| 03.12.24 | KIMMTRAK recommended for funding by NICE for uveal melanoma patients |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
